Antimicrobial resistance: international control strategies, with a focus on limited-resource settings

International Journal of Antimicrobial Agents

Volumn 32, Issue 1, 2008, Pages 1-9

  DiazGranados, Carlos A ^a   Cardo, Denise M ^b   McGowan Jr , John E ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Anti infective agents; Developing countries; Drug resistance; Health policy; Microbial

Indexed keywords

ANTIBIOTIC RESISTANCE; COMMUNICABLE DISEASE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE PRACTICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LABORATORY DIAGNOSIS; MULTIDRUG RESISTANCE; PATIENT CARE; PATIENT EDUCATION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SHORT SURVEY; TUBERCULOSIS;

ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DRUG RESISTANCE, MICROBIAL; HEALTH POLICY; HUMANS;

EID: 44949261872     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.03.002     Document Type: Short Survey

References (93)

1. Gould I.M. Antimicrobials: an endangered species?. Int J Antimicrob Agents 30 (2007) 383-384
2. Zhang R., Eggleston K., Rotimi V., and Zeckhauser R.J. Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Global Health 2 (2006) 6
3. Paterson D.L. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43 Suppl. 2 (2006) S43-S48
4. Byarugaba D.K. A view on antimicrobial resistance in developing countries and responsible risk factors. Int J Antimicrob Agents 24 (2004) 105-110
5. Okeke I.N., Laxminarayan R., Bhutta Z.A., Duse A.G., Jenkins P., O'Brien T.F., et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis 5 (2005) 481-493
6. Wensing A.M., van de Vijver D.A., Angarano G., Asjo B., Balotta C., Boeri E., et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 192 (2005) 958-966
7. Gandhi N.R., Moll A., Sturm A.W., Pawinski R., Govender T., Lalloo U., et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368 (2006) 1575-1580
8. Raviglione M.C., and Smith I.M. XDR tuberculosis-implications for global public health. N Engl J Med 356 (2007) 656-659
9. Olliaro P. Drug resistance hampers our capacity to roll back malaria. Clin Infect Dis 41 Suppl. 4 (2005) S247-S257
10. Kshirsagar N.A. Malaria: anti malarial resistance and policy ramifications and challenges. J Postgrad Med 52 (2006) 291-293
11. DiazGranados CA, McGowan JE, Jr. Resistance as a public health problem. In: Mayers DL, Sobel JD, Ouelette M, Lerner S, editors. Antimicrobial Drug Resistance Handbook. Totowa, New Jersey: Humana Press, 2008, in press.
12. Van Rie A., and Enarson D. XDR tuberculosis: an indicator of public-health negligence. Lancet 368 (2006) 1554-1556
13. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 42 Suppl. 2 (2006) S82-S89
14. McGowan Jr. J.E. Economic impact of antimicrobial resistance. Emerg Infect Dis 7 (2001) 286-292
15. Howard D.H., Scott 2nd R.D., Packard R., and Jones D. The global impact of drug resistance. Clin Infect Dis 36 Suppl. 1 (2003) S4-S10
16. Wang Y.C., and Lipsitch M. Upgrading antibiotic use within a class: tradeoff between resistance and treatment success. Proc Natl Acad Sci USA 103 (2006) 9655-9660
17. World Health Organization. Overcoming antimicrobial resistance. World Health Organization Report on Infectious Diseases 2000. WHO/CDS/2000.2. Geneva, Switzerland: WHO; 2000. Available at: http://www.who.int/infectious-disease-report/2000/index.html [accessed 19 March 2008].
18. Wise R., Hart T., Cars O., Streulens M., Helmuth R., Huovinen P., et al. Antimicrobial resistance. Is a major threat to public health. BMJ 317 (1998) 609-610
19. Dellit T.H., Owens R.C., McGowan Jr. J.E., Gerding D.N., Weinstein R.A., Burke J.P., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44 (2007) 159-177
20. Hart C.A., and Kariuki S. Antimicrobial resistance in developing countries. BMJ 317 (1998) 647-650
21. Laxminarayan R., and Malani A. Extending the cure: policy responses to the growing threat of antibiotic resistance (2007), Resources for the Future, Washington, DC
22. Scott 2nd R.D., Solomon S.L., and McGowan Jr. J.E. Applying economic principles to health care. Emerg Infect Dis 7 (2001) 282-285
23. World Health Organization. WHO global strategy for containment of antimicrobial resistance: executive summary (2001), WHO, Geneva, Switzerland
24. McDade J.E., and Hausler Jr. W.J. Modernization of public health laboratories in a privatization atmosphere. J Clin Microbiol 36 (1998) 609-613
25. Cancel D. In Venezuela, two public-health systems grow apart. Lancet 370 (2007) 473-474
26. Sirinavin S., and Dowell S.F. Antimicrobial resistance in countries with limited resources: unique challenges and limited alternatives. Semin Pediatr Infect Dis 15 (2004) 94-98
27. Struelens M.J. Multidisciplinary antimicrobial management teams: the way forward to control antimicrobial resistance in hospitals. Curr Opin Infect Dis 16 (2003) 305-307
28. Stein G.E. Antimicrobial resistance in the hospital setting: impact, trends, and infection control measures. Pharmacotherapy 25 (2005) 44S-54S
29. Pallecchi L., Bartoloni A., Fiorelli C., Mantella A., Di Maggio T., Gamboa H., et al. Rapid dissemination and diversity of CTX-M extended-spectrum beta-lactamase genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America. Antimicrob Agents Chemother 51 (2007) 2720-2725
30. Lynch P., Pittet D., Borg M.A., and Mehtar S. Infection control in countries with limited resources. J Hosp Infect 65 Suppl. 2 (2007) 148-150
31. Duerink D.O., Lestari E.S., Hadi U., Nagelkerke N.J., Severin J.A., Verbrugh H.A., et al. Determinants of carriage of resistant Escherichia coli in the Indonesian population inside and outside hospitals. J Antimicrob Chemother 60 (2007) 377-384
32. Cosgrove S.E., and Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 36 (2003) 1433-1437
33. DiazGranados C.A., Zimmer S.M., Klein M., and Jernigan J.A. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 41 (2005) 327-333
34. Song X., Srinivasan A., Plaut D., and Perl T.M. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol 24 (2003) 251-256
35. Lodise T.P., and McKinnon P.S. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 52 (2005) 113-122
36. Kwa A.L., Low J.G., Lee E., Kurup A., Chee H.L., and Tam V.H. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn Microbiol Infect Dis 58 (2007) 99-104
37. Howard D.H. Resistance-induced antibiotic substitution. Health Econ 13 (2004) 585-595
38. Rello J., Vidaur L., Sandiumenge A., Rodriguez A., Gualis B., Boque C., et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 32 (2004) 2183-2190
39. Kollef M.H. Optimizing antibiotic therapy in the intensive care unit setting. Crit Care 5 (2001) 189-195
40. Okeke I.N., Aboderin O.A., Byarugaba D.K., Ojo K.K., and Opintan J.A. Growing problem of multidrug-resistant enteric pathogens in Africa. Emerg Infect Dis 13 (2007) 1640-1646
41. Goldmann D.A., and Huskins W.C. Control of nosocomial antimicrobial-resistant bacteria: a strategic priority for hospitals worldwide. Clin Infect Dis 24 Suppl. 1 (1997) S139-S145
42. Simonsen G.S., Tapsall J.W., Allegranzi B., Talbot E.A., and Lazzari S. The antimicrobial resistance containment and surveillance approach-a public health tool. Bull World Health Organ 82 (2004) 928-934
43. Okeke I.N., Klugman K.P., Bhutta Z.A., Duse A.G., Jenkins P., O'Brien T.F., et al. Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis 5 (2005) 568-580
44. Pradier C., Bentz L., Spire B., Tourette-Turgis C., Morin M., Souville M., et al. Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials 4 (2003) 121-131
45. Damani N. Simple measures save lives: an approach to infection control in countries with limited resources. J Hosp Infect 65 Suppl. 2 (2007) 151-154
46. Rosenthal V.D., Guzman S., Pezzotto S.M., and Crnich C.J. Effect of an infection control program using education and performance feedback on rates of intravascular device-associated bloodstream infections in intensive care units in Argentina. Am J Infect Control 31 (2003) 405-409
47. Guerra C.M., Pereira C.A., Neves Neto A.R., Cardo D.M., and Correa L. Physicians' perceptions, beliefs, attitudes, and knowledge concerning antimicrobial resistance in a Brazilian teaching hospital. Infect Control Hosp Epidemiol 28 (2007) 1411-1414
48. Siegel J.D., Rhinehart E., Jackson M., and Chiarello L. Health Care Infection Control Practices Advisory Committee 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 35 Suppl. 2 (2007) S65-S164
49. World Health Organization. Global tuberculosis control. WHO report 2006. WHO/HTM/TB/2006.361. Geneva, Switzerland: WHO; 2006.
50. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in healthcare settings. Atlanta, GA: US Centers for Disease Control and Prevention; 2006. http://www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf [accessed 21 December 2007].
51. Owens Jr. R.C., and Rice L. Hospital-based strategies for combating resistance. Clin Infect Dis 42 Suppl. 4 (2006) S173-S181
52. Williams R.J., and Ryan M.J. Surveillance of antimicrobial resistance-an international perspective. BMJ 317 (1998) 651
53. Alliance for Prudent Use of Antibiotics. Executive summary: global antimicrobial resistance alerts and implications. Clin Infect Dis 41 Suppl. 4 (2005) S221-S223
54. Getahun H., Harrington M., O'Brien R., and Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 369 (2007) 2042-2049
55. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide 2000-2004. MMWR Morb Mortal Wkly Rep 55 (2006) 301-305
56. WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance: anti-tuberculosis drug resistance in the world. Third Global Report. WHO/HTM/TB/2004.343. Geneva, Switzerland: World Health Organization; 2003.
57. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006 revision. http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf [accessed 14 February 2007].
58. Zimmerman P.A. Help or hindrance? Is current infection control advice applicable in low- and middle-income countries? A review of the literature. Am J Infect Control 35 (2007) 494-500
59. Chaitram J.M., Jevitt L.A., Lary S., and Tenover F.C. The World Health Organization's External Quality Assurance System Proficiency Testing Program has improved the accuracy of antimicrobial susceptibility testing and reporting among participating laboratories using NCCLS methods. J Clin Microbiol 41 (2003) 2372-2377
60. Raza M.W., Kazi B.M., Mustafa M., and Gould F.K. Developing countries have their own characteristic problems with infection control. J Hosp Infect 57 (2004) 294-299
61. O'Brien T.F. The global epidemic nature of antimicrobial resistance and the need to monitor and manage it locally. Clin Infect Dis 24 Suppl. 1 (1997) S2-S8
62. Morris A.K., and Masterton R.G. Antibiotic resistance surveillance: action for international studies. J Antimicrob Chemother 49 (2002) 7-10
63. Bogaards J.A., and Goudsmit J. Meeting the immense need for HAART in resource-poor settings. J Antimicrob Chemother 52 (2003) 743-746
64. Mwaluko G., Wringe A., Todd J., Glynn J.R., Crampin A.C., Jaffar S., et al. Use of data from HIV counselling and testing services for HIV surveillance in Africa. Lancet 369 (2007) 612-613
65. Chretien J.P., Fukuda M., and Noedl H. Improving surveillance for antimalarial drug resistance. JAMA 297 (2007) 2278-2281
66. Moszynski P. New regulations aim to prevent international health crises. BMJ 334 (2007) 1243
67. Larson E. Community factors in the development of antibiotic resistance. Annu Rev Public Health 28 (2007) 2.1-2.13
68. Grimshaw J.M., Shirran L., Thomas R., Mowatt G., Fraser C., Bero L., et al. Changing provider behavior: an overview of systematic reviews of interventions. Med Care 39 Suppl. 2 (2001) II2-II45
69. Kushel M.B., Colfax G., Ragland K., Heineman A., Palacio H., and Bangsberg D.R. Case management is associated with improved antiretroviral adherence and CD4+ cell counts in homeless and marginally housed individuals with HIV infection. Clin Infect Dis 43 (2006) 234-242
70. Jones D.L., Ishii M., LaPerriere A., Stanley H., Antoni M., Ironson G., et al. Influencing medication adherence among women with AIDS. AIDS Care 15 (2003) 463-474
71. Smith S.R., Rublein J.C., Marcus C., Brock T.P., and Chesney M.A. A medication self-management program to improve adherence to HIV therapy regimens. Patient Educ Couns 50 (2003) 187-199
72. Levy S.B., and O'Brien T.F. Global antimicrobial resistance alerts and implications. Clin Infect Dis 41 Suppl. 4 (2005) S219-S220
73. Aiello A.E., King N.B., and Foxman B. Ethical conflicts in public health research and practice: antimicrobial resistance and the ethics of drug development. Am J Public Health 96 (2006) 1910-1914
74. Oliver T.R. The politics of public health policy. Annu Rev Public Health 27 (2006) 195-233
75. Metlay J.P., Powers J.H., Dudley M.N., Christiansen K., and Finch R.G. Antimicrobial drug resistance, regulation, and research. Emerg Infect Dis 12 (2006) 183-190
76. Thiam S., LeFevre A.M., Hane F., Ndiaye A., Ba F., Fielding K.L., et al. Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA 297 (2007) 380-386
77. Hill S., and Pang T. Leading by example: a culture change at WHO. Lancet 369 (2007) 1842-1844
78. Brooks J.T., Ochieng J.B., Kumar L., Okoth G., Shapiro R.L., Wells J.G., et al. Surveillance for bacterial diarrhea and antimicrobial resistance in rural western Kenya 1997-2003. Clin Infect Dis 43 (2006) 393-401
79. Malani P.N. Addressing poverty and human development-synonymous with infection control. Infect Control Hosp Epidemiol 28 (2007) 1321-1322
80. Nyazema N., Viberg N., Khoza S., Vyas S., Kumaranayake L., Tomson G., et al. Low sale of antibiotics without prescription: a cross-sectional study in Zimbabwean private pharmacies. J Antimicrob Chemother 59 (2007) 718-726
81. Siringi S. Over-the-counter sale of antimalaria drugs stalls Kenyan disease strategy. Lancet 357 (2001) 1862
82. Sato K., Bartlett P.C., and Saeed M.A. Antimicrobial susceptibility of Escherichia coli isolates from dairy farms using organic versus conventional production methods. J Am Vet Med Assoc 226 (2005) 589-594
83. Allegranzi B., and Pittet D. Healthcare-associated infection in developing countries: simple solutions to meet complex challenges. Infect Control Hosp Epidemiol 28 (2007) 1323-1327
84. Samb B., Celletti F., Holloway J., Van Damme W., De Cock K.M., and Dybul M. Rapid expansion of the health workforce in response to the HIV epidemic. N Engl J Med 357 (2007) 2510-2514
85. Blomberg B., Olsen B.E., Hinderaker S.G., Langeland N., Gasheka P., Jureen R., et al. Antimicrobial resistance in urinary bacterial isolates from pregnant women in rural Tanzania: implications for public health. Scand J Infect Dis 37 (2005) 262-268
86. Sarkar P., and Gould I.M. Antimicrobial agents are societal drugs: how should this influence prescribing?. Drugs 66 (2006) 893-901
87. Mamun K.Z., Tabassum S., Shears P., and Hart C.A. A survey of antimicrobial prescribing and dispensing practices in rural Bangladesh. Mymensingh Med J 15 (2006) 81-84
88. Hansen L.A., Vermeulen L.C., Bland S., and Wetterneck T.B. Guideline for low-cost antimicrobial use in the outpatient setting. Am J Med 120 (2007) 295-302
89. Pelletier Jr. L.L. Hospital usage of parenteral antimicrobial agents: a gradated utilization review and cost containment program. Infect Control 6 (1985) 226-230
90. Fraser G.L., Stogsdill P., Dickens Jr. J.D., Wennberg D.E., Smith Jr. R.P., and Prato B.S. Antibiotic optimisation. An evaluation of patient safety and economic outcomes. Arch Intern Med 157 (1997) 1689-1694
91. Molbak K. Spread of resistant bacteria and resistance genes from animals to humans-the public health consequences. J Vet Med B Infect Dis Vet Public Health 51 (2004) 364-369
92. Fishman N. Antimicrobial stewardship. Am J Infect Control 34 Suppl. 1 (2006) S55-S63 [discussion S64-73]
93. Heymann D.L. Resistance to anti-infective drugs and the threat to public health. Cell 124 (2006) 671-675